Publications by authors named "Wojciech Kacper Szlasa"
Dent Med Probl
October 2024
Article Synopsis
- Avelumab is an antibody that targets PD-L1 in cancer cells, focusing on its effects on two potential cancer targets, CD15 and IL-17RA, which are influenced by the STAT3 protein.
- The study aimed to see if treating renal cancer cells with avelumab affects CD15 and IL-17RA expression and how STAT3 mediates this regulation.
- Results showed that avelumab treatment reduced STAT3 levels, increased CD15 expression in certain cancer cells, and altered IL-17RA levels only in healthy cells, highlighting the complex role these proteins play in cancer therapy.
